Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003463 · ClinicalTrials.gov registry record · Phase 1
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003463 is a Phase 1 study that has completed, run by Duke University.
The verdict
NCT00003463, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.
Interventions
- DRUG carmustine
- DRUG irinotecan hydrochloride
- PROCEDURE surgical procedure
- DRUG polifeprosan 20 with carmustine implant
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003463
The ClinicalTrials.gov registry entry for NCT00003463 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which carmustine is the first listed.
NCT00003463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003463 about?
NCT00003463 is a clinical study titled "Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent ...
What is the current status of trial NCT00003463?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00003463?
The interventions under investigation include: carmustine (DRUG), irinotecan hydrochloride (DRUG), surgical procedure (PROCEDURE), polifeprosan 20 with carmustine implant (DRUG).
Who is sponsoring clinical trial NCT00003463?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.